01541 宜明昂科－Ｂ
IMMUNEONCO-B
IMMUNEONCO-B
| Listing Date | 2023/09/05 |
| Listing Price | 18.600 |
Quote
Subscription Result
- Subscription Rate9.98x
- Guarantee One Lot Size10 lot
- One Lot Success Rate11.56%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. founded in June 2015 in the PRC, it is a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies.
--
The Group have developed its Core Product, IMM01, an innovative clinical-stage CD47-targeted molecule. IMM01 is being developed for the treatment of various blood cancers and solid tumors in combination with other agents. Including IMM01, its pipeline consists of 14 drug candidates featured by a comprehensive innate-immunity-based asset portfolio targeting CD47 and other novel immune checkpoints, with eight ongoing clinical programs.
--
Its core business model is to in-house discover, develop and commercialize novel immuno-oncology therapies. It may also collaborate with third parties on the clinical development and commercialization of drug candidates. It is collaborating with Sunshine Guojian to conduct clinical trials evaluating a combination therapy using CIPTERBIN® (inetetamab, a HER2 mAb) and IMM01 for HER2-positive solid tumors in mainland China, and Sunshine Guojian will drive and fund relevant clinical trials.
--
As of 17 August 2023, the Group owned nine issued patents in the PRC, eight issued patents in the U.S.. In relation to its Core Product, IMM01, it owned one patent family, which includes one issued patent in the PRC, one issued patent in the U.S., one issued patent in the European Union (EU) and one issued patent in Japan.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 17.15M H shares |
| No. of International Offer Shares | 15.43M H shares |
| No. of HK Offer Shares | 1.71M H shares |
| Offer Price | $18.60 |
| Stock Code | 1541 |
| Sponsor(s) | Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Fosun International Securities Limited, CMB International Capital Limited, BOCI Asia Limited, ICBC International Securities Limited, Soochow Securities International Brokerage Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Aug 24 (Thu) - noon, Aug 29 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Sep 04 (Mon) |
| Result Announcement Date | On or before Sep 04 (Mon) |
| Result Announcement Date | On or before Sep 04 (Mon) |
| Dealings in Shares commence on | Sep 05, 2023. (Tue) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $18.60 |
| Capitalization (H Shares) | 4.23B |
| NAV / share ($) | $2.75 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 18.6, the net proceeds raised would be HKD 233.40M, of which |
| 40% : Used for ongoing and planned clinical trials, preparation for registration filings, and planned commercial launch of Core Product, IMM01 (SIRPα-Fc fusion protein) |
| 28% : Used for ongoing and planned clinical trials, preparation for registration filings, and planned commercial launch of Key Products, IMM0306 (CD47×CD20), IMM2902 (CD47×HER2) and IMM2520 (CD47×PD-L1) |
| 10% : Used for the planned clinical trial of IMM47 (CD24 mAb) |
| 5% : Used for the ongoing clinical trials of IMM2510 (VEGF×PD-L1) and IMM27M (CTLA4 ADCC-enhanced mAb) |
| 7% : Used for construction of our new manufacturing facility in Zhangjiang Science City, Shanghai |
| 5% : Used for continuous preclinical research and development of multiple preclinical- and discovery-stage assets |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).